Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15%
Key Insights Institutions' substantial holdings in Oruka Therapeutics implies that they have significant influence ...
Oruka Therapeutics (ORKA) Gets a Buy from TD Cowen
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) today. The company’s shares closed ...
Promising Potential of Oruka Therapeutics’ ORKA-001 in Psoriasis Treatment
Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) and keeping the price target at ...
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Recommendation of “Buy” by Analysts
Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have earned a consensus rating of “Buy” from the eight ...
What is HC Wainwright’s Forecast for ORKA FY2024 Earnings?
Equities researchers at HC Wainwright reduced their FY2024 EPS estimates for Oruka Therapeutics in a research report issued ...
Morningstar22d
Oruka Therapeutics Inc ORKA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
WBOY22d
Paragon Therapeutics Appoints Susanna High as Chief Executive Officer
Spyre Therapeutics, Oruka Therapeutics, Jade Biosciences, and Crescent Biopharma. They have collectively raised approximately $2.7 billion and currently have four programs in clinical development.
Mena FN24d
Oruka Therapeutics To Present At Piper Sandler’S 36Th Annual Healthcare Conference
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin ...